PCRX RSI Chart
Last 7 days
1.0%
Last 30 days
-5.9%
Last 90 days
-7.0%
Trailing 12 Months
-37.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 681.8M | 0 | 0 | 0 |
2023 | 669.2M | 669.2M | 665.7M | 675.0M |
2022 | 580.5M | 614.3M | 654.1M | 666.8M |
2021 | 443.0M | 503.1M | 513.3M | 541.5M |
2020 | 435.4M | 408.3M | 421.1M | 429.6M |
2019 | 354.0M | 372.5M | 393.7M | 421.0M |
2018 | 292.0M | 305.1M | 321.2M | 337.3M |
2017 | 280.2M | 281.5M | 280.5M | 286.6M |
2016 | 256.2M | 266.6M | 272.8M | 276.4M |
2015 | 355.2M | 367.2M | 377.3M | 249.0M |
2014 | 110.6M | 140.7M | 169.4M | 333.5M |
2013 | 42.9M | 47.7M | 62.4M | 85.6M |
2012 | 19.6M | 28.3M | 32.9M | 39.1M |
2011 | 13.6M | 14.2M | 13.6M | 15.7M |
2010 | 14.9M | 14.8M | 14.7M | 14.6M |
2009 | 0 | 0 | 0 | 15.0M |
2008 | 0 | 0 | 0 | 13.9M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 08, 2024 | pace gary w | sold | -2,754,000 | 30.6 | -90,000 | - |
Mar 07, 2024 | pace gary w | sold | -870,598 | 30.81 | -28,257 | - |
Mar 06, 2024 | pace gary w | sold | -31,628 | 29.67 | -1,066 | - |
Feb 05, 2024 | williams kristen | acquired | - | - | 33,700 | chief administrative officer |
Feb 05, 2024 | gaugler daryl | acquired | - | - | 33,700 | chief operating officer |
Jan 02, 2024 | riker lauren | sold (taxes) | -5,088 | 32.00 | -159 | senior vice president, finance |
Jan 02, 2024 | slonin jonathan | acquired | - | - | 5,000 | chief medical officer |
Jan 02, 2024 | lee frank d. | acquired | - | - | 99,520 | chief executive officer |
Aug 02, 2023 | winston roy | sold | -17,751 | 34.875 | -509 | chief medical officer |
Jul 05, 2023 | riker lauren bullaro | sold | -25,019 | 38.91 | -643 | senior vice president, finance |
Which funds bought or sold PCRX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 06, 2024 | Leisure Capital Management | sold off | -100 | -11,151 | - | -% |
May 06, 2024 | Spectrum Wealth Counsel, LLC | unchanged | - | -2,712 | 17,532 | -% |
May 06, 2024 | Quantbot Technologies LP | reduced | -32.31 | -100,895 | 142,944 | 0.01% |
May 06, 2024 | Jefferies Financial Group Inc. | added | 82.8 | 1,074,370 | 2,137,800 | 0.01% |
May 06, 2024 | HighTower Advisors, LLC | added | 64.97 | 128,000 | 424,000 | -% |
May 06, 2024 | DUALITY ADVISERS, LP | added | 1.77 | -136,811 | 1,016,390 | 0.10% |
May 06, 2024 | Retirement Planning Co of New England, Inc. | sold off | -100 | -211,887 | - | -% |
May 06, 2024 | Van Hulzen Asset Management, LLC | added | 1.32 | -140,000 | 1,005,000 | 0.07% |
May 06, 2024 | Parallel Advisors, LLC | reduced | -20.36 | -2,931 | 6,516 | -% |
May 06, 2024 | NEW YORK LIFE INVESTMENT MANAGEMENT LLC | added | 46.68 | 77,754 | 365,455 | -% |
Unveiling Pacira BioSciences Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Pacira BioSciences Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 357.8B | 85.6B | 9.3 | 4.18 | ||||
MRK | 330.2B | 61.4B | 143.19 | 5.38 | ||||
AMGN | 161.1B | 29.5B | 42.82 | 5.46 | ||||
PFE | 156.8B | 46.5B | -112.94 | 3.37 | ||||
GILD | 81.5B | 27.1B | 14.39 | 3.01 | ||||
TEVA | 15.6B | 15.8B | -27.14 | 0.99 | ||||
MID-CAP | ||||||||
ALKS | 4.2B | 1.7B | 9.58 | 2.41 | ||||
PRGO | 4.1B | 4.6B | -533.77 | 0.9 | ||||
BHC | 2.7B | 9.0B | -5.97 | 0.3 | ||||
AMPH | 2.1B | 644.4M | 14.96 | 3.19 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.38 | 2.07 | ||||
TXMD | 23.2M | 1.3M | -2.26 | 17.8 | ||||
ACRX | 17.0M | - | -0.92 | 0.22 | ||||
AGRX | 2.7M | 19.6M | -0.19 | 0.14 | ||||
ACOR | 1.1M | 117.6M | 0 | 0.01 |
Pacira BioSciences Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -7.8% | 167 | 181 | 164 | 169 | 160 | 172 | 167 | 169 | 158 | 159 | 128 | 136 | 119 | 131 | 117 | 76.00 | 106 | 122 | 105 | 103 | 91.00 |
Cost Of Revenue | -0.6% | 47.00 | 48.00 | 40.00 | 48.00 | 49.00 | 62.00 | 51.00 | 51.00 | 36.00 | 39.00 | 35.00 | 35.00 | 31.00 | 35.00 | 30.00 | 22.00 | 30.00 | 32.00 | 22.00 | 25.00 | 27.00 |
Costs and Expenses | 3.9% | 154 | 148 | 146 | 130 | 163 | 182 | 146 | 138 | 141 | 155 | 96.00 | 101 | 100 | 112 | 100 | 83.00 | 89.00 | 121 | 102 | 97.00 | 90.00 |
Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 121 | 102 | 97.00 | 90.00 |
S&GA Expenses | 9.5% | 72.00 | 66.00 | 68.00 | 65.00 | 71.00 | 64.00 | 61.00 | 65.00 | 64.00 | 52.00 | 48.00 | 51.00 | 49.00 | 53.00 | 53.00 | 43.00 | 45.00 | 54.00 | 50.00 | 49.00 | 47.00 |
R&D Expenses | -6.3% | 18.00 | 19.00 | 21.00 | 19.00 | 17.00 | 18.00 | 19.00 | 26.00 | 22.00 | 16.00 | 12.00 | 13.00 | 16.00 | 15.00 | 15.00 | 14.00 | 16.00 | 20.00 | 20.00 | 18.00 | 14.00 |
EBITDA Margin | 19.5% | 0.28* | 0.23* | 0.19* | 0.18* | 0.16* | 0.22* | 0.21* | 0.23* | 0.22* | 0.22* | 0.24* | 0.21* | - | - | - | - | - | - | - | - | - |
Interest Expenses | -2.1% | 3.00 | 3.00 | 3.00 | 4.00 | 10.00 | 11.00 | 10.00 | 9.00 | 10.00 | 10.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 5.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 |
Income Taxes | -47.3% | 5.00 | 9.00 | 6.00 | 12.00 | -6.94 | -7.97 | 3.00 | 2.00 | 0.00 | -1.07 | 7.00 | 7.00 | 2.00 | -1.82 | -123 | -0.04 | 0.00 | 1.00 | 0.00 | -1.60 | 0.00 |
Earnings Before Taxes | -59.5% | 14.00 | 34.00 | 17.00 | 38.00 | -26.47 | -18.07 | 2.00 | 22.00 | 7.00 | -6.20 | 24.00 | 26.00 | 13.00 | 13.00 | 6.00 | -7.31 | 9.00 | -3.54 | -5.82 | 1.00 | -2.52 |
EBT Margin | 63.4% | 0.15* | 0.09* | 0.01* | -0.01* | -0.03* | 0.02* | 0.04* | 0.08* | 0.09* | 0.10* | 0.15* | 0.11* | - | - | - | - | - | - | - | - | - |
Net Income | -63.9% | 9.00 | 25.00 | 11.00 | 26.00 | -19.54 | -10.10 | -0.69 | 20.00 | 7.00 | -5.13 | 18.00 | 19.00 | 10.00 | 15.00 | 130 | -7.27 | 8.00 | -4.89 | -6.09 | 3.00 | -2.77 |
Net Income Margin | 66.3% | 0.10* | 0.06* | 0.01* | -0.01* | -0.02* | 0.02* | 0.03* | 0.06* | 0.07* | 0.08* | 0.12* | 0.35* | - | - | - | - | - | - | - | - | - |
Free Cashflow | 1.0% | 46.00 | 46.00 | 41.00 | 40.00 | 13.00 | 37.00 | 37.00 | 18.00 | 23.00 | 14.00 | 47.00 | 20.00 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 0.6% | 1,583 | 1,574 | 1,534 | 1,542 | 1,523 | 1,681 | 1,734 | 1,734 | 1,891 | 2,075 | 1,356 | 1,326 | 1,288 | 1,275 | 1,220 | 866 | 821 | 831 | 807 | 788 | 719 |
Current Assets | 6.5% | 543 | 510 | 447 | 429 | 376 | 498 | 533 | 526 | 667 | 866 | 822 | 793 | 720 | 652 | 659 | 456 | 432 | 409 | 379 | 395 | 509 |
Cash Equivalents | 20.1% | 184 | 153 | 99.00 | 87.00 | 36.00 | 104 | 109 | 122 | 227 | 586 | 134 | 106 | 67.00 | 100 | 125 | 79.00 | 55.00 | 78.00 | 85.00 | 60.00 | 215 |
Inventory | -7.3% | 97.00 | 104 | 97.00 | 92.00 | 93.00 | 96.00 | 97.00 | 101 | 104 | 99.00 | 67.00 | 65.00 | 65.00 | 65.00 | 69.00 | 67.00 | 60.00 | 58.00 | 60.00 | 53.00 | 47.00 |
Net PPE | -1.2% | 172 | 174 | 176 | 180 | 182 | 184 | 194 | 191 | 190 | 188 | 159 | 153 | 145 | 137 | 126 | 113 | 108 | 105 | 105 | 105 | 107 |
Goodwill | 0.0% | 163 | 163 | 163 | 163 | 163 | 163 | 157 | 146 | 146 | 145 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 101 | 38.00 |
Liabilities | -1.9% | 691 | 704 | 703 | 734 | 755 | 906 | 964 | 977 | 1,182 | 1,345 | 637 | 639 | 637 | 655 | 636 | 478 | 447 | 476 | 461 | 446 | 392 |
Current Liabilities | -4.0% | 93.00 | 97.00 | 94.00 | 109 | 99.00 | 148 | 132 | 133 | 305 | 521 | 226 | 229 | 232 | 253 | 86.00 | 71.00 | 80.00 | 108 | 96.00 | 83.00 | 59.00 |
Long Term Debt | 0.2% | 399 | 399 | 398 | 397 | 405 | 405 | 404 | 404 | 403 | 339 | 326 | 322 | 317 | 313 | 456 | 314 | 310 | 306 | 302 | 298 | 294 |
LT Debt, Current | 0% | 9.00 | 9.00 | 9.00 | 9.00 | - | - | - | - | 160 | 350 | 156 | 154 | 152 | 150 | - | - | - | - | - | - | - |
LT Debt, Non Current | -100.0% | - | 399 | 398 | 397 | 405 | 405 | 404 | 404 | 403 | 339 | 326 | 322 | 317 | 313 | 456 | 314 | 310 | 306 | 302 | 298 | 294 |
Shareholder's Equity | 2.5% | 892 | 870 | 832 | 808 | 768 | 775 | 770 | 757 | 710 | 730 | 719 | 687 | 651 | 620 | 585 | 388 | 374 | 355 | 346 | 342 | 328 |
Retained Earnings | 8.4% | -97.82 | -106 | -131 | -142 | -168 | -148 | -138 | -137 | -157 | -211 | -206 | -224 | -243 | -253 | -268 | -398 | -391 | -399 | -394 | -388 | -391 |
Additional Paid-In Capital | 1.3% | 990 | 977 | 963 | 951 | 936 | 924 | 909 | 895 | 868 | 942 | 925 | 911 | 894 | 873 | 852 | 785 | 766 | 754 | 740 | 730 | 718 |
Shares Outstanding | 0.1% | 47.00 | 46.00 | 46.00 | 46.00 | 46.00 | 46.00 | 45.00 | 45.00 | 45.00 | 44.00 | 44.00 | 44.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 1,300 | - | - | - | 1,900 | - | - | - | 1,600 | - | - | - | 1,600 | - | - | - | 848 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 3.2% | 49,101 | 47,584 | 44,438 | 43,499 | 19,128 | 42,037 | 42,654 | 29,806 | 30,777 | 23,215 | 60,287 | 30,134 | 12,081 | 46,667 | 39,781 | -15,624 | 6,208 | 25,904 | 18,354 | 22,763 | 3,499 |
Share Based Compensation | 5.9% | 13,151 | 12,420 | 12,530 | 10,955 | 11,990 | 12,677 | 12,682 | 11,544 | 11,189 | 10,891 | 10,784 | 10,461 | 10,110 | 10,897 | 10,954 | 9,222 | 8,847 | 9,189 | 9,244 | 7,783 | 7,434 |
Cashflow From Investing | -285.5% | -15,530 | 8,374 | -4,342 | 7,326 | 66,183 | 11,189 | -47,516 | 19,161 | -208,019 | 66,918 | -35,077 | 3,033 | -55,664 | -82,317 | -202,847 | 36,123 | -28,566 | -30,795 | 5,625 | -181,799 | 78,481 |
Cashflow From Financing | -58.3% | -2,817 | -1,779 | -27,787 | 440 | -153,905 | -58,511 | -7,775 | -153,657 | -181,585 | 361,409 | 3,052 | 5,908 | 10,325 | 10,363 | 209,758 | 3,464 | -1,281 | -2,020 | 1,423 | 3,737 | 530 |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenues: | |||
Total revenues | $ 674,978 | $ 666,823 | $ 541,533 |
Operating expenses: | |||
Cost of goods sold | 184,669 | 199,295 | 140,255 |
Research and development | 76,257 | 84,797 | 55,545 |
Selling, general and administrative | 269,441 | 254,516 | 199,345 |
Amortization of acquired intangible assets | 57,288 | 57,288 | 13,553 |
Contingent consideration (gains) charges, acquisition-related charges and other | (352) | 10,903 | 42,911 |
Total operating expenses | 587,303 | 606,799 | 451,609 |
Income from operations | 87,675 | 60,024 | 89,924 |
Other (expense) income: | |||
Interest income | 11,444 | 4,542 | 896 |
Interest expense | (20,306) | (39,976) | (31,750) |
Loss on early extinguishment of debt | (16,926) | 0 | 0 |
Other, net | (186) | (11,288) | (2,666) |
Total other expense, net | (25,974) | (46,722) | (33,520) |
Income before income taxes | 61,701 | 13,302 | 56,404 |
Income tax (expense) benefit | (19,746) | 2,607 | (14,424) |
Net income | $ 41,955 | $ 15,909 | $ 41,980 |
Net income per share: | |||
Basic net income per common share (in dollars per share) | $ 0.91 | $ 0.35 | $ 0.95 |
Diluted net income per common share (in dollars per share) | $ 0.89 | $ 0.34 | $ 0.92 |
Weighted average common shares outstanding: | |||
Basic (in shares) | 46,222 | 45,521 | 44,262 |
Diluted (in shares) | 51,979 | 46,538 | 45,630 |
Net product sales | |||
Revenues: | |||
Total revenues | $ 672,245 | $ 664,150 | $ 538,966 |
Royalty revenue | |||
Revenues: | |||
Total revenues | 2,733 | 2,673 | 2,442 |
Collaborative licensing and milestone revenue | |||
Revenues: | |||
Total revenues | $ 0 | $ 0 | $ 125 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 153,298 | $ 104,139 |
Short-term available-for-sale investments | 125,283 | 184,512 |
Accounts receivable, net | 105,556 | 98,397 |
Inventories, net | 104,353 | 96,063 |
Prepaid expenses and other current assets | 21,504 | 15,223 |
Total current assets | 509,994 | 498,334 |
Noncurrent available-for-sale investments | 2,410 | 37,209 |
Fixed assets, net | 173,927 | 183,512 |
Right-of-use assets, net | 61,020 | 70,877 |
Goodwill | 163,243 | 163,243 |
Intangible assets, net | 483,258 | 540,546 |
Deferred tax assets | 144,485 | 160,309 |
Investments and other assets | 36,049 | 27,170 |
Total assets | 1,574,386 | 1,681,200 |
Current liabilities: | ||
Accounts payable | 15,698 | 15,220 |
Accrued expenses | 64,243 | 89,785 |
Lease liabilities | 8,801 | 9,121 |
Current portion of convertible senior notes, net | 8,641 | 0 |
Current portion of long-term debt, net | 0 | 33,648 |
Total current liabilities | 97,383 | 147,774 |
Convertible senior notes, net | 398,594 | 404,767 |
Long-term debt, net | 115,202 | 251,056 |
Lease liabilities | 54,806 | 64,802 |
Contingent consideration | 24,698 | 28,122 |
Other liabilities | 13,573 | 9,669 |
Total liabilities | 704,256 | 906,190 |
Commitments and contingencies (Note 20) | ||
Stockholders’ equity: | ||
Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at December 31, 2023 and 2022 | 0 | 0 |
Common stock, par value $0.001; 250,000,000 shares authorized; 46,481,174 and 45,927,790 shares issued and outstanding at December 31, 2023 and 2022, respectively | 46 | 46 |
Additional paid-in capital | 976,633 | 924,095 |
Accumulated deficit | (106,796) | (148,751) |
Accumulated other comprehensive income (loss) | 247 | (380) |
Total stockholders’ equity | 870,130 | 775,010 |
Total liabilities and stockholders’ equity | $ 1,574,386 | $ 1,681,200 |
 | Mr. David M. Stack |
---|---|
 | pacira.com |
 | Pharmaceuticals |
 | 715 |